1. Investment Snapshot
2. Thesis
3. Valuation & Price Target
4. Business & Product Moat
5. People & Governance
6. Market & Macro
7. Financial Quality
8. Risk Register
9. Prediction Market
10. 𝕏 Posts
Discussion
1. Investment Snapshot
2. Thesis
3. Valuation & Price Target
4. Business & Product Moat
5. People & Governance
6. Market & Macro
7. Financial Quality
8. Risk Register
9. Prediction Market
10. 𝕏 Posts
Discussion
1. Investment Snapshot
2. Valuation
Discussion
Symbol
TCBP
Event Date
2022-02-11
Sector
Health Care
Subsector
Biotechnology
Offer Range
$4.25
Shares Offered
4.12M
27.71M
$96.1M
14.9%
Implied Upside vs Midpoint
Description
TCB based in Scotland, is a clinical-stage biopharmaceutical company focused on developing novel immunotherapy products that are based on its proprietary allogeneic gamma delta T (abbreviated as GD-T) cell platform. Harnessing the innate ability of GD-Ts has enabled TCB to develop a range of clinical-stage cell therapies designed to combat identified cancers and viral infections. TCB is embarking on phase II-into-pivotal (phase III) clinical studies, which are expected to commence in the fourth quarter of 2021, following United Kingdom and European Union regulations, with a view to launching its first oncology product, which will be for the treatment of acute myeloid leukemia (abbreviated as AML). The Company plans to conduct similar clinical trials in the United States in 2022 for the treatment of AML following an application to the FDA in H1 2022. Clinical results generated thus far have enabled TCB to obtain FDA orphan drug status for its method of treatment of AML. In addition to unmodified allogenic GD-Ts for treatment of blood cancers, TCB is also developing an innovative range of genetically modified chimeric antigen receptor modified T cell (abbreviated as CAR-T) products for treatment of solid cancers. TCB believes that solid cancers are more difficult to treat than blood cancers and may require addition of a chimeric antigen receptor (abbreviated as CAR) to (i) help therapeutic cells ‘navigate’ into diseased cancerous tissue, and (ii) retain therapeutic cells in-situ at the lesion for maximum efficacy. In response to the recent pandemic, because GD-Ts are natural killers of virally infected cells, as well as cancerous cells, TCB is planning clinical studies to treat patients with both acute and long term COVID-19 symptoms. We believe acute COVID-19 trials will start in the fourth quarter of 2021. --- Our principal executive offices are located in Scotland, United Kingdom, with a mailing address of Maxim 1, 2 Parklands Way, Holytown, Motherwell, ML1 4WR, United Kingdom and our telephone number at that location is +44 (0) 141 433 7557. Our website address is www.tcbiopharm.com.
TC BioPharm (Holdings) plc annual income statement and balance sheet, FY 2021 to FY 2024, as reported in SEC filings (GBP).
| Metric | FY 2021 | FY 2022 | FY 2023 | FY 2024 |
|---|---|---|---|---|
| Revenue | GBP 2.0M | GBP 3.8M | GBP 21.6 | — |
| Operating income | (GBP 9.3M) | (GBP 12.1M) | (GBP 14.2M) | (GBP 12.8M) |
| Net income | (GBP 13.6M) | (GBP 1.3M) | (GBP 5.9M) | (GBP 12.2M) |
| Metric | FY 2021 | FY 2022 | FY 2023 | FY 2024 |
|---|---|---|---|---|
| Total assets | GBP 8.0M | GBP 11.3M | GBP 8.9M | GBP 8.3M |
| Total liabilities | GBP 24.6M | GBP 11.0M | GBP 6.2M | GBP 5.3M |
| Total equity | (GBP 16.6M) | GBP 331K | GBP 2.7M | GBP 3.0M |
| Cash & equivalents | GBP 1.6M | GBP 4.8M | GBP 2.5M | GBP 1.2M |